

# Curriculum vitae - Prof. Dr. Viktor Magdolen

## Professional career

<b>1977-1988</b>	Study of biological science at the Ludwig-Maximilians-University, Munich: genetics, biochemistry, zoology. Diploma in genetics. Ph.D. thesis: "Characterization of constitutive and inducible promoter structures in yeast"
<b>1988-1993</b>	Postdoctoral fellowships: - Institut für Genetik und Mikrobiologie, Munich (Prof. Dr. W. Bandlow) - University of California, Berkeley, U.S.A. (Prof. Dr. D. Drubin) - Max-Planck-Institut für Biochemie, Martinsried (Prof. Dr. F. Lottspeich)
<b>1993 - to date</b>	Klinische Forschergruppe der Frauenklinik der Technischen Universität München (Director: Prof. Dr. M. Kiechle)
<b>1997</b>	Co-founder of WILEX Biotechnology GmbH (now Heidelberg Pharma AG)
<b>2001</b>	<i>Habilitation</i> in Experimental Gynecology
<b>2001 - to date</b>	Lecturer at the Medical Faculty of the TU München ( <i>Privat-Dozent: 2001 - 2010</i> )
<b>2010</b>	apl. Professor for Experimental Gynecology
<b>2014</b>	Guest professor, Université Pierre et Marie Curie (Sorbonne), Paris, Oktober 2014
<b>2016</b>	Co-founder of Therawis Diagnostics GmbH ( <a href="http://www.therawis.com">http://www.therawis.com</a> )

## Research activities

- 170 publications in scientific journals with an "impact factor"-listing (Nov 2018)
- 37 publications in other scientific journals or books (no abstracts)
- 9 patents (world-wide, EU, or Germany)
- Editor of two book volumes on kallikrein-related peptidases:  
Kallikrein-related peptidases.  
Volume 1: Characterization, regulation, and interactions within the protease web.  
Volume 2: Novel cancer-related biomarkers.  
Magdolen, V, Sommerhoff CP, Fritz H, Schmitt M (eds.), De Gruyter, Berlin
- Supervision of 19 completed dissertations (12x Dr. med., 6x Dr. rer. nat.) plus 2 diploma/master theses
- Supervision of students from Greece, Slovenia, Slovakia, Poland, France, Australia, and China within programs supported by the European Union (Madame Curie Training Site Program; Socrates / Erasmus Program), Centre de Coopération Universitaire Franco-Bavarois (CCUFB), the German Academic Exchange Service (DAAD), and the China Scholarship Council (CSC)
- Board member of the multicenter research project SFB 469 der LMU München (2002-2003); Scientific Advisor, Wilex AG, München (1997 - 2007); Member of the Editorial Board of *Biological Chemistry*; board member of the E.K.Frey-E.Werle Foundation of the Henning L.Voigt Family (since 2011); board member of the Henner Graeff Foundation (since 2013)
- Conference Secretary, 16<sup>th</sup> International Congress of the International Society for Fibrinolysis and Proteolysis, 2002, München; Organization (2005 - 2012) and Lecturer (2005 - to date) at the annual "*Winter School on Proteinases and their Inhibitors and Receptors*" in Tiers, Italy; Organization of the 3rd Symposium on Kallikreins and Kallikrein-related Peptidases in Munich, September 2009
- Director of the German-Australian Network on Personalized Cancer Medicine (DAAD; 2013-2016)
- External reviewer of dissertations at the Oxford Brookes University, England; Institute Pasteur, Paris, France; University of Salzburg, Austria; University of Antwerp, Belgium; Medical Faculty of the TU Dresden, Germany; Medical Faculty of the Albert-Ludwigs-Universität Freiburg, Germany; and Macquarie University, Sydney, Australia
- Reviewer for 22 scientific journals with an "impact factor"-listing: *Biochimica Biophysica Acta*; *Biological Chemistry*; *Cancer Letters*; *Cancer Research*; *Carcinogenesis*; *Cellular and Molecular Life Sciences*; *Clin Chem Lab Med*, *Current Medicinal Chemistry*; *European Journal of Biochemistry*; *Expert Opinion on Therapeutic Patents*; *FEBS Letters*; *International Journal of Cancer*; *International Journal of Gynecological Cancer*; *International Journal of Oncology*; *Oncogene*; *Oncotarget*; *PLoS ONE*; *Proteomics*; *Theranostics*; *Thrombosis and Haemostasis*; *Thrombosis Research*; *Tumour Biology*
- Reviewer for German (*Deutsche Forschungsgemeinschaft [DFG]* and *Dr. Mildred Scheel-Stiftung*), Austrian (*FWF Wissenschaftsfonds* and *Österreichische Nationalbank [Jubiläumsfonds]*), Belgian (*Research Foundation Flanders [FWO]*), Italian (*Italian Association for Cancer Research [AIRC]*), and Scottish (*Worldwide Cancer Research*) research funding organizations; external assessor for the *National Health and Medical Research Council, Australia*
- Frey-Werle Promotion Prize (E.K.Frey-E.Werle Foundation of the Henning L. Voigt Family) for the contributions covering both basic and clinically oriented studies in the field of the kallikrein-related peptidases (2011)